abstract |
The present invention relates to stable low viscosity antibody formulations comprising high concentrations of anti-IL4R antibodies. In some embodiments, the invention generally comprises from about 100 mg / mL to about 200 mg / mL of an antibody or fragment thereof that specifically binds human interleukin-4 receptor alpha ((hIL-4Rα), about 50 mM. A stable antibody formulation comprising: from about 0.002% to about 400 mM viscosity modifier; from about 0.002% to about 0.2% nonionic surfactant; In some embodiments, the present invention is directed to containers, dosage forms and / or kits, hi some embodiments, the present invention is stable. It is directed to methods of making and using antibody formulations. |